News Archives - Page 638 of 1677

TuesdayJan 10, 2023 11:49 am

NetworkNewsBreaks – QSAM Biosciences Inc. (QSAM) Releases Shareholder Letter Outlining 2022 Updates, 2023 Milestone Goals

QSAM Biosciences (OTCQB: QSAM), a company developing next-generation therapeutic radiopharmaceuticals, including Samarium-153-DOTMP, or CycloSam(R), for the treatment of bone cancer and related diseases, has provided key updates and milestone goals in a shareholder letter; the letter is from QSAM Biosciences executive chair and cofounder C. Richard Piazza and CEO and cofounder Douglas Baum. The letter noted that QSAM is developing its lead therapeutic radiopharmaceutical drug candidate, CycloSam, to treat cancer that has either originated in the bone or has metastasized to the bone from the breast, prostate, lung or other organs. During 2022, CycloSam received rare pediatric disease designation for the…

TuesdayJan 10, 2023 11:36 am

NetworkNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Key Milestones, 2023 Business Outlook

InMed Pharmaceuticals (NASDAQ: INM), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today outlined key accomplishments from 2022 and provided a business update and catalysts for 2023. “Over the course of 2022, we strengthened our position as a leader in rare cannabinoid R&D, creating a unique offering as the only company that has the breadth and depth in cannabinoid drug research, development and significant manufacturing know-how,” said Eric A. Adams, InMed president and CEO. “Despite the many economic pressures affecting businesses on a global scale, including challenging capital markets, particularly in biotech, InMed…

TuesdayJan 10, 2023 11:16 am

NetworkNewsBreaks – EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQB: EVGIF) Signs $31M Definitive Agreement with Roynat Capital, Export Development Canada

EverGen (TSX.V: EVGN) (OTCQB: EVGIF), Canada’s renewable natural gas (“RNG”) infrastructure platform, has entered a definitive agreement with existing lenders Roynat Capital (a subsidiary of the Bank of Nova Scotia) and Export Development Canada (EDC). According to the announcement, the agreement outlines the terms for a $31 million syndicated senior term loan, with Roynat and EDC each providing 50% of the proceeds. The company noted that funds will be used to support the upgrade and construction of EverGen’s RNG facilities, to provide $15 million for refinancing of existing debt and construction at Fraser Valley Biogas (“FVB”) and to provide $16…

TuesdayJan 10, 2023 10:54 am

NetworkNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Begins Trading on Next-Gen Marketplace

Jupiter Wellness (NASDAQ: JUPW), a company focused on hair, skin and sexual wellness, announced that today at 10 a.m. EST, the company will start trading on Upstream under the ticker symbol JUPW. A revolutionary trading app for digital securities and NFTs, Upstream is powered by Horizon Fintex and MERJ Exchange Limited. The company noted that a digital collectible NFT commemorating the dual listing would be available for Upstream participants to claim using the code: JUPW. Through Upstream, investors around the world can invest in JUPW by downloading the Upstream app from their preferred app store and creating an account. Transactions…

MondayJan 09, 2023 2:14 pm

NetworkNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Kicks Off New Year with Multiple New Contracts, Announces Planned Path to Profitability

Knightscope (NASDAQ: KSCP), a developer of advanced physical security technologies focused on enhancing U.S. security operations, announced that it has secured four new contracts in a successful start of 2023. Under the contracts, Knightscope will deploy three K5 Autonomous Security Robots (“ASRs”) and five K1 Blue Light Towers. The deployment locations include an existing Knightscope channel partner’s regional corporate office in Jacksonville, Florida, an Illinois-based casino, as well as the parking lot of an apartment complex for a well-known learning institution. A teaching hospital has also purchased five K1 Blue Light Towers to improve communications and safety on its New…

MondayJan 09, 2023 12:35 pm

NetworkNewsBreaks – HIVE Blockchain Technologies Ltd. (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBFA) Issues December 2022 Production Update

HIVE Blockchain Technologies (NASDAQ: HIVE) (TSX.V: HIVE) (FSE: HBFA) today announced production figures from its global bitcoin (“BTC”) operations for the month of December 2022 and the calendar year 2022. The company reportedly produced 213.8 bitcoin in December, plus USD $3.15 million of income from its energy price hedging and grid balancing strategy. Additionally, HIVE produced crypto assets with a value of 4,752 bitcoin (based on daily average price of BTC) in 2022, which is an 18% increase from the prior year. “We are very happy to be producing over 213 bitcoin this month, while also earning over USD $3…

MondayJan 09, 2023 12:11 pm

NetworkNewsBreaks – AmeriCann Inc. (ACAN) Announces Record Fiscal Year-End and Quarterly Results

AmeriCann (OTCQB: ACAN), a cannabis company that develops state-of-the-art cultivation, product manufacturing and distribution facilities, today released financial and operational results for its fiscal year and quarter ending September 2022. “Our focus on cost efficiency has produced some of the strongest adjusted operating EBITDA margins in the industry,” said CFO Ben Barton. “We look forward to investing the cash flow we are generating to further expand operations at the Massachusetts Cannabis Center and to produce even better financial results for shareholders.” To view the full press release, visit https://nnw.fm/YCYFA About AmeriCann Inc. AmeriCann is a cannabis company that develops cultivation,…

MondayJan 09, 2023 11:56 am

NetworkNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Incorporates New Subsidiary to Capitalize on Drug Development Incentives in Australia

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announced the incorporation of a new subsidiary to capitalize on drug development incentives in Australia. The company also announced its expanded focus to investigate other products addressing acute medical needs due to substances of abuse such as alcohol, as well as the appointments of Dr. Jeremy Chataway, Dr.Ashwin Dhanda and Dr. Anh Lê to its scientific and clinical expert committee. “We are excited about the incorporation of FSD Pharma Australia, where…

MondayJan 09, 2023 10:37 am

NetworkNewsBreaks — MetAlert Inc. (MLRT) Featured in Ludlow Research Analyst Brief

MetAlert (OTC: MLRT), a pioneer in location-sensitive, health-monitoring devices and wearable technology products for remote patient monitoring, spotlighted in a recent Q&A analyst report released by Ludlow Research. In the article, MLRT representations respond to questions, providing an overview of the company and discussing specific topics investors and shareholders might be interested in. The report delved into the company’s recent restructuring, name change and ticker symbol change, with the company stating that “we waited patiently to do this until we had a clean balance sheet and were prepared to take the company to the next level.” The report noted that…

MondayJan 09, 2023 10:30 am

NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Releases Status Update on Clinical Development Programs

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), is discussing upcoming priorities and near-term milestones regarding the status of its two clinical programs aimed at addressing multiple mental health conditions: CYB003 and CYB004. Designed for the treatment of Major Depressive Disorder (“MDD”), CYB003 is currently in a phase 1/2a clinical trial. CYB003 is a deuterated psilocybin analog. CYBN anticipates releasing an interim readout from the trial by the end of February 2023, which will provide an initial understanding of the safety and pharmacokinetic (“PK”) profile of the substance in humans. This interim data will…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Breaks Categories: News